Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: Results of a post-marketing surveillance study in Japan

Drugs in R and D

Volumn 10, Issue 3, 2010, Pages 133-145

  Ishiguchi, Tsuneo ^a   Takahashi, Shoki ^b  

^a AICHI MEDICAL UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

Adverse drug reactions; Gadoterate meglumine; Magnetic resonance imaging; Research and development; therapeutic use

Indexed keywords

GADOTERATE MEGLUMINE; MAGNESCOPE; UNCLASSIFIED DRUG;

ABNORMAL SENSATION; ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD PRESSURE; COUGHING; CREATININE BLOOD LEVEL; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; FOLLOW UP; FOREIGN BODY; GASTROINTESTINAL SYMPTOM; HEAT SENSATION; HOSPITALIZATION; HUMAN; JAPAN; KIDNEY DISEASE; KIDNEY FUNCTION TEST; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FUNCTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PRURITUS; RECOMMENDED DRUG DOSE; SIDE EFFECT; SKIN DISEASE; SNEEZING; TASTE; THORAX PAIN; TREMOR; TUMOR BLEEDING; UREA BLOOD LEVEL; URTICARIA; VISUAL DISORDER; VOMITING;

ADOLESCENT; ADULT; AGED; CHILD; CONTRAST MEDIA; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; JAPAN; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PRODUCT SURVEILLANCE, POSTMARKETING; RISK FACTORS;

EID: 79953171522     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.2165/11539140-000000000-00000     Document Type: Article

References (24)

1. Idee JM, Port M, Raynal I, et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 2006;20(6):563-76 (Pubitemid 44760175)
2. Ruehm SG, Goyen M, Barkhausen J, et al. Rapid magnetic resonance angiography for detection of atherosclerosis. Lancet 2001;357(9262):1086-91 (Pubitemid 32322540)
3. Claussen C, Laniado M, Schorner W, et al. Gadolinium-DTPA in MR imaging of glioblastomas and intracranial metastases. AJNR Am J Neuroradiol 1985;6(5):669-74 (Pubitemid 15014459)
4. Healy ME, Hesselink JR, Press GA, et al. Increased detection of intracranial metastases with intravenous Gd-DTPA. Radiology 1987;165(3):619-24 (Pubitemid 18003178)
5. Meaney JF, Weg JG, Chenevert TL, et al. Diagnosis of pulmonary embolism with magnetic resonance angiography. N Engl J Med 1997;336(20):1422-7 (Pubitemid 27208601)
6. Semelka RC, Helmberger TK. Contrast agents for MR imaging of the liver. Radiology 2001;218(1):27-38
7. Thomsen HS, Marckmann P, Logager VB. Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Cancer Imaging 2007;7:130-7 (Pubitemid 47570591)
8. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21(4):1104-8
9. Kirchin MA, Runge VM. Contrast agents for magnetic resonance imaging: safety update. Top Magn Reson Imaging 2003;14(5):426-35 (Pubitemid 37521732)
10. Laurent S, Elst LV, Muller RN. Compŕtive study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging 2006;1(3):128-37
11. Port M, Idee JM, Medina C, et al. Stability of gadolinium chelates and their biological consequences: new dt́ and some comments. Br J Radiol 2008;81(963):258-9 (Pubitemid 351547886)
12. Allard M, Doucet D, Kien P, et al. Experimental study of DOTA-gadolinium: pharmacokinetics and pharmacologic properties. Invest Radiol 1988;23(1):S271-4
13. Herborn CU, Honold E, Wolf M, et al. Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA). Invest Radiol 2007;42(1):58-62 (Pubitemid 46072553)
14. Oudkerk M, Sijens PE, Van Beek EJ, et al. Safety and efficacy of dotarem (Gd-DOTA) versus magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system. Invest Radiol 1995;30(2):75-8
15. Brugieres P, Gaston A, Degryse HR, et al. Randomised double blind trial of the safety and efficacy of two gadolinium complexes (Gd-DTPA and Gd-DOTA). Neuroradiology 1994;36(1):27-30 (Pubitemid 24001251)
16. Beaudouin E, Kanny G, Blanloeil Y, et al. Anaphylactic shock induced by gadoterate meglumine (DOTAREM). Eur Ann Allergy Clin Immunol 2003;35(10):382-5 (Pubitemid 38029741)
17. Hasdenteufel F, Luyasu S, Renaudin JM, et al. Anaphylactic shock after first exposure to gadoterate meglumine: two case reports documented by positive allergy assessment. J Allergy Clin Immunol 2008;121(2):527-8 (Pubitemid 351215162)
18. DeHoratius DM, Cowper SE. Nephrogenic systemic fibrosis: an emerging threat among renal patients. Semin Dial 2006;19(3):191-4 (Pubitemid 43742654)
19. Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 2003;15(6):785-90 (Pubitemid 38156308)
20. Scheinfeld N. Nephrogenic fibrosing dermopathy: a comprehensive review for the dermatologist. Am J Clin Dermatol 2006;7(4):237-47 (Pubitemid 44231919)
21. Cowper S. Nephrogenic fibrosing dermopathy [online]. Available from URL: http://www.icnfdr.org [Accessed 2010 Aug. 27]
22. Penfield JG, Reilly RF. Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents? Semin Dial 2008;21(2):129-34
23. Kimura J, Ishiguchi T, Matsuda J, et al. Human compŕtive study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents. Radiat Med 2005;23(5):322-6 (Pubitemid 41265349)
24. Tsushima Y, Tḱhashi-Taketomi A, Endo K. Nephrogenic systemic fibrosis in Jṕn: advisability of keeping the administered dose as low as possible. Radiology 2008;247(3):915-6